Lyra Therapeutics, Inc. Common Stock
LYRA Real Time Price USDRecent trades of LYRA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by LYRA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Implantable scaffolds for treatment methods of sinusitus Aug. 20, 2024
-
Patent Title: Implantable scaffolds for treatment of sinusitis Jul. 16, 2024
-
Patent Title: Implantable scaffolds for treatment of sinusitis and method of reducing inflammation May. 23, 2023
-
Patent Title: Scaffold loading and delivery systems Apr. 13, 2021
-
Patent Title: Implantable scaffolds for treatment of sinusitis Dec. 15, 2020
-
Patent Title: Scaffold loading and delivery systems Dec. 08, 2020
-
Patent Title: Implantable scaffolds for treatment of sinusitus Oct. 20, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of LYRA in WallStreetBets Daily Discussion
Recent insights relating to LYRA
Recent picks made for LYRA stock on CNBC
ETFs with the largest estimated holdings in LYRA
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view LYRA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.